This is in accordance with the demonstration that PD-1 enhances regulatory properties in Treg cells and inhibition of anti-tumor activity of CD4 Teff cells in MM, indicating a role of PD-1 in the MM clinical outcome [49]. Here, CD4 is linked to Miyoshi myopathy.